Goldman Sachs Reveals Significant Stake in Life Sciences Firm

Goldman Sachs has disclosed its significant stake in QIAGEN, a Netherlands-based life sciences company. According to the Dutch Authority for the Financial Markets (AFM), Goldman Sachs holds approximately 2.93% of Qiagen's capital and voting rights through a combination of shares, derivatives, and convertible instruments linked to the company.

The detailed breakdown shows exposure via ordinary shares, swaps, options, warrants, and convertible bonds across various Goldman Sachs entities, underscoring significant but non-controlling financial involvement in QIAGEN. While Qiagen notes it is not responsible for the accuracy of the AFM data, the filing highlights continued attentiveness to transparency around substantial shareholdings for market participants.

QIAGEN specializes in sample and assay technologies used in molecular diagnostics, applied testing, academic research, and pharmaceutical development. Its shares are listed on multiple European exchanges, as well as the NYSE and Swiss venues, reflecting a broad international investor base.